
Elecsys pTau217 is the first blood test designed to signal and rule out Alzheimer’s disease, and has now been cleared for use in Europe, Roche announced on Tuesday.
The blood test, developed in collaboration with Eli Lilly and Company, received the CE Mark – confirming its safety and performance, and allowing its use in the European Union.